Clinical trial
Assessment of a Weight Management Program for Weight Gain in Patients With…
NCT00485823 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00485823 |
|---|---|
| Title | Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia |
| Official title | The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenic Disorders |
| Intervention type | Drug, Procedure |
| Interventions | Olanzapine Hydrochloride, Weight Management Program |
| Enrollment | 48 |
| Start date | Dec 1, 2002 |
| Completion | Sep 1, 2003 |
| First posted | Jun 13, 2007 |
| Last update posted | Jun 13, 2007 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: